Sign inJoin waitlistJoin the waitlist

Paolo Caimi

Medical Director, Cleveland Clinic Cancer Center Clinical Trials Unit, Case Comprehensive Cancer Center · Case Western Reserve University

Credentials: · · · · ·

History

Cleveland Clinic Cancer Center Clinical Trials Unit · Case Western Reserve University
Present
Clinical Trials Unit · Case Western Reserve University
Present
Case Western Reserve University/University Hospitals Cleveland Medical Center
Present

Case Western Reserve University/University Hospitals Cleveland Medical Center
2007–2010
Internal Medicine
Sinai Hospital of Baltimore
2004–2007
San Juan De Dios Hospital
2002–2003
Weatherhead School of Management Case Western Reserve University
Case Western Reserve Univ Sch of Med
1998–2002

Research

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
The Lancet Oncology · 2021 · First of 18 authors · Corresponding · 394 citations
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology · 2021 · 260 citations
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Blood · 2018 · 214 citations

Marcos de Lima
49 papers
Brenda Cooper
31 papers
Brian Hill
29 papers
Hillard Lazarus
26 papers
Leland Metheny
20 papers · 1 as a fellow
Benjamin Tomlinson
19 papers · 1 as a fellow
Ehsan Malek
18 papers
Folashade Otegbeye
17 papers · 1 as a fellow
KB
Kirsten Boughan
17 papers
BK
Brad Kahl
16 papers
Deepa Jagadeesh
16 papers
Nancy Bartlett
14 papers

Clinical trials

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Principal investigator · Recruiting · Phase 1
Paolo Caimi, MD
2026–2027
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Principal investigator · Recruiting · Phase 1
Paolo Caimi, MD
2025–2027
Collection of Peripheral Blood From Patients With Hematologic Malignancies With Thrombocytopenia
Principal investigator · Completed
Case Comprehensive Cancer Center
2025
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma
Principal investigator · Recruiting · Phase 1
Luminary Therapeutics
2023–2025